- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00269958
A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery
16. mai 2011 oppdatert av: Janssen-Ortho Inc., Canada
A Double-Blind, Phase II, Placebo-Controlled Study to Determine the Safety and Efficacy of r-HuEPO in Reducing Transfusion Requirements in Patients Undergoing Total Hip Joint Replacement Surgery
The purpose of this study is to evaluate the safety and effectiveness of two different dosing schedules of epoetin alfa versus placebo for decreasing the need for blood transfusions and preventing the occurrence of severe anemia during the period of time around total hip replacement surgery.
Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.
Studieoversikt
Detaljert beskrivelse
Major surgical procedures may require blood transfusions both during and after the operation.
Agents that can increase the rate of red blood cell production would reduce the need for blood transfusions and reduce the occurrence of anemia.
Epoetin alfa is a genetically engineered form of a natural hormone, erythropoietin, that is used to treat anemia by stimulating red blood cell production.
This is a randomized, double-blind, placebo-controlled, parallel group, multicenter study in patients scheduled for total hip replacement surgery.
This study will assess the effectiveness of epoetin alfa (starting either 5 or 10 days before hip replacement surgery and continuing though 3 days after surgery) in reducing the need for blood transfusions and the occurrence of anemia during the time period surrounding surgery.
Hip replacement can be either the initial implant surgery or a second surgery on the same hip.
Eligible patients will be assigned to one of three treatment groups.
Group 1 will receive daily placebo injections under the skin for 14 days; Group 2 will receive a longer (14-day) course of daily epoetin alfa injections under the skin; and Group 3 will receive a shorter (9-day) course of daily epoetin alfa injections under the skin.
Patients in Groups 2 and 3 will receive 300 units of epoetin alfa per kilogram of body weight per day in each daily injection.
All patients will receive oral iron supplementation beginning 3 weeks prior to surgery and continuing through 1 week after surgery.
All patients will also receive low-dose coumadin (sodium warfarin) for 7 days after surgery to prevent clotting in the deep veins.
Effectiveness will be determined by the number of patients requiring transfusions and the number of patients who develop anemia (as measured by a hemoglobin level < 80 grams per liter).
Effectiveness will also be determined by the total number of transfusions required, changes in red blood cell variables (hemoglobin, hematocrit, the number of developing red blood cells (reticulocytes), changes in the iron stores in the patient's blood, intensity of nursing care required, well-being assessments (measures of pain, shortness of breath, and energy level), and the number of days in the hospital after surgery.
Safety evaluations will include the incidence of blood clots in the deep veins of the lower limbs, the incidence and severity of other adverse events, and changes in clinical laboratory test results and vital signs.
The study hypothesis is that patients treated with epoetin alfa before, during, and after hip replacement surgery will require fewer blood transfusions and have a reduced occurrence of anemia compared with patients treated with placebo, and that the shorter course of epoetin alfa dosing (9 days) is as effective as the longer epoetin alfa course (14 days).
300 units epoetin alfa per kilogram (U/kg) injected under the skin 5 or 10 days before surgery, the day of surgery, and 3 days after surgery; or placebo injection for 14 days.
Subjects receiving epoetin alfa for 5 days also received placebo for 5 days before starting epoetin alfa.
Studietype
Intervensjonell
Registrering (Faktiske)
208
Fase
- Fase 2
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 85 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patients scheduled for elective, first-time hip-replacement surgery or a second hip-replacement surgery (with surgery taking place within 48 hours of the scheduled time)
- having a baseline hemoglobin between 110 and 160 grams per liter
- with no significantly abnormal values for laboratory tests that would indicate an impaired ability to respond to epoetin alfa.
Exclusion Criteria:
- Patients with a primary hematologic disease
- having any clinically significant disease/dysfunction of the neurologic, pulmonary, endocrine, cardiovascular, gastrointestinal, or genitourinary systems
- who have had a seizure disorder in the past 5 years, or who are currently on anticonvulsant therapy
- having uncontrolled high blood pressure
- currently experiencing an ongoing blood loss
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Proportion of patients needing blood transfusions; proportion of patients who develop anemia (defined as hemoglobin <80 grams per liter).
|
Sekundære resultatmål
Resultatmål |
---|
Number of blood units transfused; changes in red cell variables (hemoglobin, hematocrit, and reticulocyte counts); iron stores; nursing needs; scores on well-being tests; number days in hospital after surgery; deep vein clots and other adverse events
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiet fullført (Faktiske)
1. desember 1991
Datoer for studieregistrering
Først innsendt
22. desember 2005
Først innsendt som oppfylte QC-kriteriene
22. desember 2005
Først lagt ut (Anslag)
26. desember 2005
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
17. mai 2011
Siste oppdatering sendt inn som oppfylte QC-kriteriene
16. mai 2011
Sist bekreftet
1. april 2010
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CR005887
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Anemi
-
Assistance Publique - Hôpitaux de ParisHar ikke rekruttert ennåAlvorlig aplastisk anemi | Idiopatisk aplastisk anemi | Moderat aplastisk anemi som krever transfusjoner
-
National Heart, Lung, and Blood Institute (NHLBI)FullførtAnemi, aplastisk | Anemi, hypoplastiskForente stater
-
University of UtahNovartisFullførtAlvorlig aplastisk anemi | Moderat aplastisk anemi | Svært alvorlig aplastisk anemiForente stater
-
Northwell HealthFullførtPure Red Cell Aplasia | Diamond Blackfan anemi | Blackfan Diamond syndrom | DBA | Medfødt hypoplastisk anemiForente stater
-
Peking University People's HospitalRekruttering
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes... og andre samarbeidspartnereRekruttering
-
Federal Research Institute of Pediatric Hematology...RekrutteringErvervet aplastisk anemiDen russiske føderasjonen
-
Jiangsu HengRui Medicine Co., Ltd.Fullført
-
Shanghai General Hospital, Shanghai Jiao Tong University...Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School... og andre samarbeidspartnereFullførtAlvorlig aplastisk anemiKina
-
Jiangsu HengRui Medicine Co., Ltd.Fullført
Kliniske studier på epoetin alfa
-
Catholic University of the Sacred HeartSOFAR S.p.A.UkjentGodartet, premalignt og ondartet gynekologisk sykdom begrenset til bekkenetItalia
-
Xiangya Hospital of Central South UniversityUkjent
-
First Affiliated Hospital Xi'an Jiaotong UniversityRekruttering
-
Peking University Third HospitalRekrutteringSkjoldbrusk øyesykdomKina
-
SOFAR S.p.A.FullførtLivmorsykdommer | Adnexal sykdommerItalia
-
University of EdinburghRekrutteringAortastenose | Karsinoid syndrom | Kjemoterapi-indusert systolisk dysfunksjonStorbritannia
-
Huashan HospitalRekrutteringNeoplasmer | Positron-utslippstomografiKina
-
UMC UtrechtHar ikke rekruttert ennåMetastatisk tykktarmskreft | Metastatisk kreft i leveren
-
Sichuan Provincial People's HospitalRekrutteringAldosteronproduserende adenomKina